LBTD (Lotus Bio-Technology Development) Debt-to-Equity: 0.00 (As of Dec. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Lotus Bio-Technology Development Debt-to-Equity?

Lotus Bio-Technology Development LBTD -99.99% Debt-to-Equity is 0.00 as of Dec. 2017.

Lotus Bio-Technology Development's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2017 was $0.00 Mil. Lotus Bio-Technology Development's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2017 was $0.00 Mil. Lotus Bio-Technology Development's Total Stockholders Equity for the quarter that ended in Dec. 2017 was $-0.06 Mil. Lotus Bio-Technology Development's debt to equity for the quarter that ended in Dec. 2017 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Lotus Bio-Technology Development's Debt-to-Equity or its related term are showing as below:

LBTD's Debt-to-Equity is not ranked *
in the Agriculture industry.
Industry Median: 0.35
* Ranked among companies with meaningful Debt-to-Equity only.

Lotus Bio-Technology Development  (OTCPK:LBTD) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Lotus Bio-Technology Development Debt-to-Equity Related Terms


Lotus Bio-Technology Development Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Lotus Bio-Technology Development's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lotus Bio-Technology Development Debt-to-Equity Chart

Lotus Bio-Technology Development Annual Data
Trend Mar11 Mar12 Mar13 Mar14 Mar15 Mar16 Mar17
Debt-to-Equity
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -0.07

Lotus Bio-Technology Development Quarterly Data
Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.07 N/A N/A 0.00

LBTD vs SNES, CVAT: Debt-to-Equity Comparison

For the Agricultural Inputs subindustry, Lotus Bio-Technology Development's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lotus Bio-Technology Development Debt-to-Equity vs Agriculture Industry

For the Agriculture industry and Basic Materials sector, Lotus Bio-Technology Development's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Lotus Bio-Technology Development's Debt-to-Equity falls into.



Lotus Bio-Technology Development Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Lotus Bio-Technology Development's Debt to Equity Ratio for the fiscal year that ended in Mar. 2017 is calculated as

Lotus Bio-Technology Development's Debt to Equity Ratio for the quarter that ended in Dec. 2017 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Lotus Bio-Technology Development (LBTD) has a Debt-to-Equity of 0.00 as of Dec. 2017. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Lotus Bio-Technology Development and its competitors.
Is Lotus Bio-Technology Development's Debt-to-Equity too high?
Lotus Bio-Technology Development's current Debt-to-Equity is 0.00.
How does Lotus Bio-Technology Development's Debt-to-Equity compare to SNES and CVAT?
Lotus Bio-Technology Development's Debt-to-Equity of 0.00 can be compared against companies in the Agriculture industry. The industry median Debt-to-Equity is 0.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for an Agriculture company?
The median Debt-to-Equity among Agriculture companies is 0.35, based on 230 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Lotus Bio-Technology Development and its competitors. For the Agriculture industry, the median Debt-to-Equity is 0.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lotus Bio-Technology Development's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lotus Bio-Technology Development stock overvalued right now?
Lotus Bio-Technology Development (LBTD) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Lotus Bio-Technology Development (LBTD), the current Debt-to-Equity is 0.00 as of Dec. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lotus Bio-Technology Development Business Description

Address 108 2559 Parkview Lane, Port Coquitlam, BC, CAN, V3C6M1
Lotus Bio-Technology Development Corp is actively seeking out new opportunities in the Organic and Bio-technology space.